Epistatic effect of cholesteryl ester transfer protein and hepatic lipase on serum high-density lipoprotein cholesterol levels

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 7, 2007, Pages 2680-2687

  Isaacs, Aaron ^a   Aulchenko, Yurii S ^a   Hofman, Albert ^a   Sijbrands, Eric J G ^a   Sayed Tabatabaei, Fakhredin A ^b   Klungel, Olaf H ^c   Maitland Van Der Zee, Anke Hilse ^c   Stricker, Bruno H Ch ^a   Oostra, Ben A ^a   Witteman, Jacqueline C M ^a   Van Duijn, Cornelia M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER TRIACYLGLYCEROL LIPASE;

AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; EPISTASIS; FEMALE; GENE MUTATION; HEART INFARCTION; HOMOZYGOSITY; HUMAN; LINEAR REGRESSION ANALYSIS; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN VARIANT; STATISTICAL MODEL;

EID: 34447133527     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0269     Document Type: Article

References (40)

1. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM 2004 Antiinflammatory properties of HDL. Circ Res 95:764-772
2. Schaefer EJ, Asztalos BF 2006 Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction. Curr Opin Lipidol 17:394-398
3. Rader DJ 2006 Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 116:3090-3100
4. Isaacs A, Sayed-Tabatabaei FA, Njajou OT, Witteman JC, van Duijn CM 2004 The -514 C → T hepatic lipase promoter region polymorphism and plasma lipids: a metaanalysis. J Clin Endocrinol Metab 89:3858-3863
5. Boekholdt SM, Thompson JF 2003 Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J Lipid Res 44: 1080-1093
6. Barter PJ 2002 Hugh Sinclair lecture: the regulation and remodelling of HDL by plasma factors. Atheroscler Suppl 3:39-47
7. Talmud PJ, Hawe E, Robertson K, Miller GJ, Miller NE, Humphries SE 2002 Genetic and environmental determinants of plasma high density lipoprotein cholesterol and apolipoprotein AI concentrations in healthy middle-aged men. Ann Hum Genet 66:111-124
8. Whiting BM, Anderson JL, Muhlestein JB, Horne BD, Bair TL, Pearson RR, Carlquist JF 2005 Candidate gene susceptibility variants predict intermediate end points but not angiographic coronary artery disease. Am Heart J 150:243-250
9. Takata M, Inazu A, Katsuda S, Miwa K, Kawashiri MA, Nohara A, Higashikata T, Kobayashi J, Mabuchi H, Yamagishi M 2006 CETP (cholesteryl ester transfer protein) promoter -1337 C > T polymorphism protects against coronary atherosclerosis in Japanese patients with heterozygous familial hypercholesterolaemia. Clin Sci (Lond) 111:325-331
10. Tobin MD, Braund PS, Burton PR, Thompson JR, Steeds R, Channer K, Cheng S, Lindpaintner K, Samani NJ 2004 Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study. Eur Heart J 25:459-467
11. Fan YM, Salonen JT, Koivu TA, Tuomainen TP, Nyyssonen K, Lakka TA, Salonen R, Seppanen K, Nikkari ST, Tahvanainen E, Lehtimaki T 2004 Hepatic lipase C-480T polymorphism modifies the effect of HDL cholesterol on the risk of acute myocardial infarction in men: a prospective population based study. J Med Genet 41:e28
12. McCaskie PA, Cadby G, Hung J, McQuillan BM, Chapman CM, Carter KW, Thompson PL, Palmer LJ, Beilby JP 2006 The C-480T hepatic lipase polymorphism is associated with HDL-C but not with risk of coronary heart disease. Clin Genet 70:114-121
13. Fan YM, Lehtimaki T, Rontu R, Ilveskoski E, Goebeler S, Kajander O, Mikkelsson J, Perola M, Karhunen PJ, Age-dependent association between hepatic lipase gene C-480T polymorphism and the risk of pre-hospital sudden cardiac death: The Helsinki Sudden Death Study. Atherosclerosis, 2006 June 19 [Epub ahead of print]
14. Liu S, Schmitz C, Stampfer MJ, Sacks F, Hennekens CH, Lindpaintner K, Ridker PM 2002 A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. Atherosclerosis 161:469-474
15. Relvas WG, Izar MC, Helfenstein T, Fonseca MI, Colovati M, Oliveira A, Ihara SS, Han SW, Las Casas Jr AA, Fonseca FA 2005 Relationship between gene polymorphisms and prevalence of myocardial infarction among diabetic and non-diabetic subjects. Atherosclerosis 178:101-105
16. Eiriksdottir G, Bolla MK, Thorsson B, Sigurdsson G, Humphries SE, Gudnason V 2001 The -629C > A polymorphism in the CETP gene does not explain the association of TaqIB polymorphism with risk and age of myocardial infarction in Icelandic men. Atherosclerosis 159:187-192
17. Corbex M, Poirier O, Fumeron F, Betoulle D, Evans A, Ruidavets JB, Arveiler D, Luc G, Tiret L, Cambien F 2000 Extensive association analysis between the CETP gene and coronary heart disease phenotypes reveals several putative functional polymorphisms and gene-environment interaction. Genet Epidemiol 19:64-80
18. Andrikopoulos GK, Richter DJ, Needham EW, Zairis MN, Karabinos EN, Gialafos EJ, Dilaveris PE, Paravolidakis KE, Kappos KG, Papasteriadis EG, Kardaras FG, Foussas SG, Stefanadis CI, Gialafos JE, Mattu RK, Toutouzas PK 2004 Association of the ile405val mutation in cholesteryl ester transfer protein gene with risk of acute myocardial infarction. Heart 90:1336-1337
19. Gudnason V, Kakko S, Nicaud V, Savolainen MJ, Kesaniemi YA, Tahvanainen E, Humphries S 1999 Cholesteryl ester transfer protein gene effect on CETP activity and plasma high-density lipoprotein in European populations. The EARS Group. Eur J Clin Invest 29:116-128
20. Isaacs A, Sayed-Tabatabaei FA, Hofman A, Oostra BA, Klungel OH, Maitland-van der Zee A, Stricker BHCh, Witteman JCM, van Duijn CM, The CETP I405V polymorphism is associated with increased HDL levels and decreased risk of myocardial infarction: the Rotterdam Study. Eur J Cardiovasc Prev Rehabil, in press
21. Stephens JW, Humphries SE 2003 The molecular genetics of cardiovascular disease: clinical implications. J Intern Med 253:120-127
22. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA 1991 Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 7:403-422
23. van Gent CM, van der Voort HA, de Bruyn AM, Klein F 1977 Cholesterol determinations. A comparative study of methods with special reference to enzymatic procedures. Clin Chim Acta 75:243-251
24. Bots ML, Hofman A, De Jong PT, Grobbee DE 1996 Common carotid intima-media thickness as an indicator of atherosclerosis at other sites of the carotid artery. The Rotterdam Study. Ann Epidemiol 6:147-153
25. Raymond M, Rousset F 1995 Genepop (version-1.2): population-genetics software for exact tests and ecumenicism. J Hered 86:248-249
26. Barter PJ, Kastelein JJ 2006 Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol 47:492-499
27. Forrester JS, Makkar R, Shah PK 2005 Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation 111:1847-1854
28. 2006 Cholesterol: the good, the bad, and the stopped trials. Lancet 368:2034
29. Motsinger AA, Ritchie MD 2006 Multifactor dimensionality reduction: an analysis strategy for modelling and detecting gene-gene interactions in human genetics and pharmacogenomics studies. Hum Genomics 2:318-328
30. Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ 2005 Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 25:2185-2191
31. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM 2006 Mechanisms of disease: proatherogenic HDL-an evolving field. Nat Clin Pract Endocrinol Metab 2:504-511
32. Dichek HL, Johnson SM, Akeefe H, Lo GT, Sage E, Yap CE, Mahley RW 2001 Hepatic lipase overexpression lowers remnant and LDL levels by a noncatalytic mechanism in LDL receptor-deficient mice. J Lipid Res 42:201-210
33. Gonzalez-Navarro H, Nong Z, Amar MJ, Shamburek RD, Najib-Fruchart J, Paigen BJ, Brewer Jr HB, Santamarina-Fojo S 2004 The ligand-binding function of hepatic lipase modulates the development of atherosclerosis in transgenic mice. J Biol Chem 279:45312-45321
34. Jessup W, Kritharides L 2000 Metabolism of oxidized LDL by macrophages. Curr Opin Lipidol 11:473-481
35. Aikawa M, Libby P 2004 The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovasc Pathol 13:125-138
36. Yamazaki K, Bujo H, Taira K, Itou N, Shibasaki M, Takahashi K, Saito Y 2004 Increased circulating malondialdehyde-modified LDL in the patients with familial combined hyperlipidemia and its relation with the hepatic lipase activity. Atherosclerosis 172:181-187
37. Tanaga K, Bujo H, Inoue M, Mikami K, Kotani K, Takahashi K, Kanno T, Saito Y 2002 Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler Thromb Vasc Biol 22:662-666
38. Bauerfeind A, Knoblauch H, Schuster H, Luft FC, Reich JG 2002 Single nucleotide polymorphism haplotypes in the cholesteryl-ester transfer protein (CETP) gene and lipid phenotypes. Hum Hered 54:166-173
39. Carr MC, Hokanson JE, Zambon A, Deeb SS, Barrett PH, Purnell JQ, Brunzell JD 2001 The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity. J Clin Endocrinol Metab 86:2831-2837
40. Redberg RF 2006 Gender differences in acute coronary syndrome: invasive versus conservative approach. Cardiol Rev 14:299-302